19 out of 21 Healthcare companies topped profit estimates this week: Earnings Scorecard
Seeking Alpha News (Sun, 4-Aug 10:54 AM ET)
Over 80% of companies that reported earnings this week beat profit estimates - Earnings Scorecard
Seeking Alpha News (Sun, 4-Aug 9:37 AM ET)
OS Therapies stock falls 20% following downsized IPO (update)
Seeking Alpha News (Thu, 1-Aug 3:44 PM ET)
REGENXBIO releases new data on DMD drug ahead of earnings
Seeking Alpha News (Thu, 1-Aug 11:34 AM ET)
Argus Research Sticks to Their Hold Rating for Pfizer (PFE)
TipRanks (Thu, 1-Aug 10:26 AM ET)
Moderna drops as lower COVID vaccine sales prompt guidance cut
Seeking Alpha News (Thu, 1-Aug 7:15 AM ET)
Pfizer’s Financial Prospects: Balancing Cost Efficiencies Against Growth Uncertainties
TipRanks (Thu, 1-Aug 2:08 AM ET)
Pfizer's Diverse Portfolio And Strong Execution Earn Analyst Praise Despite Patent Concerns
Benzinga (Wed, 31-Jul 2:56 PM ET)
UBS Sticks to Their Hold Rating for Pfizer (PFE)
TipRanks (Wed, 31-Jul 2:06 PM ET)
Pfizer inks deal with Telescope Innovations to boost R&D capabilities
Seeking Alpha News (Wed, 31-Jul 11:57 AM ET)
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Pfizer trades on the NYSE stock market under the symbol PFE.
As of August 5, 2024, PFE stock price declined to $29.89 with 17,598,275 million shares trading.
PFE has a beta of 0.15, meaning it tends to be less sensitive to market movements. PFE has a correlation of 0.01 to the broad based SPY ETF.
PFE has a market cap of $169.37 billion. This is considered a Large Cap stock.
Last quarter Pfizer reported $13 billion in Revenue and $.60 earnings per share. This beat revenue expectation by $263 million and exceeded earnings estimates by $.14.
In the last 3 years, PFE stock traded as high as $61.71 and as low as $25.20.
The top ETF exchange traded funds that PFE belongs to (by Net Assets): VTI, VOO, SCHD, SPY, IVV.
PFE stock has underperformed the market in the last year with a return of -10.7%, while SPY returned +17.1%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in PFE shares. However, PFE has outperformed the market in the last 3 month and 2 week periods, returning +10.9% and +1.1%, while SPY returned +3.3% and -5.3%, respectively. This indicates PFE has been having a stronger performance recently.
PFE support price is $29.94 and resistance is $30.93 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PFE stock will trade within this expected range on the day.